LABORATORIO REIG JOFRE S.A. (ES:RJF)
BME:RJF
Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.40
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€218.06M
Enterprise Value€307.02M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)41.7
Beta0.33
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.04
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€349.90M
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (branded + CDMO)Having both branded pharmaceutical sales and contract development/manufacturing (CDMO) services creates durable revenue diversification. CDMO contracts can provide multi-year supply visibility and higher-value manufacturing margins, while branded products sustain direct market access and commercial know-how.
Historic Revenue Expansion (2020–2024)A multi-year expansion through 2024 indicates underlying product adoption and capacity utilization prior to the 2025 setback. That prior growth suggests the company has proven commercial channels and production scale which could support recovery once demand or pricing pressures normalize.
Moderate Historical Leverage And Equity GrowthHistorically moderate leverage and steady equity growth provide structural balance-sheet resilience. This mix supports borrowing capacity for capex or biotech partnerships while limiting interest burden in normal conditions, helping sustain investment in manufacturing and product pipelines.
Bears Say
2025 Sharp Revenue And Margin DeteriorationA sudden, large drop in revenue coupled with near-break-even margins is a structural concern: it erodes operating leverage, reduces reinvestment capacity, and may indicate lost market share or pricing pressure. Recovery could require sustained commercial or product remediation over multiple quarters.
Weak And Volatile Cash GenerationNegative free cash flow and steep OCF decline undermine the firm's ability to self-fund capex, R&D, or working capital needs. Given prior volatility (negative in 2021 and 2025), inconsistent cash conversion raises refinancing and liquidity risk, pressuring strategic flexibility over months.
Rising Leverage And Weak Returns In 2025Higher leverage alongside sharply reduced ROE signals diminished capacity to generate shareholder returns while increasing fixed-cost burdens. Elevated debt levels constrain maneuverability for investments or acquisitions and raise vulnerability to interest or covenant stress if earnings remain depressed.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.40 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €218.06M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on Feb 27, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.049 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Options Prices
Currently, No data available
---